Similar articles

• Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma.

  Mitchell MS, Abrams J, Thompson JA, Kashani-Sabet M, DeConti RC, Hwu WJ, Atkins MB, Whitman E, Ernstoff MS, Haluska FG, Jakowatz JG, Das Gupta TK, Richards JM, Samlowski WE, Costanzi JJ, Aronson FR, Deisseroth AB, Dudek AZ, Jones VE. Mitchell MS, et al. J Clin Oncol. 2007 May 20;25(15):2078-85. doi: 10.1200/JCO.2006.10.1709. J Clin Oncol. 2007. PMID: 17513813 Clinical Trial.
• Melanoma adjuvant therapy.

  Tarhini AA, Thalanayar PM. Tarhini AA, et al. Hematol Oncol Clin North Am. 2014 Jun;28(3):471-89. doi: 10.1016/j.hoc.2014.02.004. Hematol Oncol Clin North Am. 2014. PMID: 24880942 Review.
• Immunotherapy as an adjuvant therapy in the management of advanced, surgically resected, melanoma.

  Kalani AD, Jack A, Montenegro G, Degliuomini J, Wallack MK. Kalani AD, et al. G Ital Dermatol Venereol. 2008 Feb;143(1):59-70. G Ital Dermatol Venereol. 2008. PMID: 18833052 Review.
• Use of adjuvant therapy in cutaneous melanoma.

  Sondak VK. Sondak VK. Expert Rev Anticancer Ther. 2001 Oct;1(3):421-6. doi: 10.1586/14737140.1.3.421. Expert Rev Anticancer Ther. 2001. PMID: 12113108 Review.
• Adjuvant therapy for malignant melanoma.

  Stoutenburg JP, Schrope B, Kaufman HL. Stoutenburg JP, et al. Expert Rev Anticancer Ther. 2004 Oct;4(5):823-35. doi: 10.1586/14737140.4.5.823. Expert Rev Anticancer Ther. 2004. PMID: 15485316 Review.